|
Total population, n = 2419
|
Without event, n = 1965
|
With event, n = 454
|
P
|
---|
Age, years
|
60.08 ± 8.97
|
59.60 ± 8.72
|
62.16 ± 9.70
|
< 0.001
|
Male, n (%)
|
1737 (71.8)
|
1422 (72.4)
|
315 (69.4)
|
0.203
|
BMI, kg/m2
|
26.21 ± 3.45
|
26.13 ± 3.40
|
26.55 ± 3.61
|
0.019
|
Heart rate, bpm
|
69.77 ± 10.15
|
69.44 ± 10.00
|
71.17 ± 10.69
|
0.002
|
SBP, mmHg
|
130.30 ± 16.52
|
129.80 ± 15.99
|
132.44 ± 18.50
|
0.005
|
DBP, mmHg
|
77.05 ± 9.90
|
77.00 ± 9.68
|
77.25 ± 10.80
|
0.661
|
Smoking, n (%)
|
1381 (57.1)
|
1127 (57.4)
|
254 (55.9)
|
0.585
|
Drinking, n (%)
|
562 (23.2)
|
468 (23.8)
|
94 (20.7)
|
0.157
|
Family history of CAD, n (%)
|
254 (10.5)
|
203 (10.3)
|
51 (11.2)
|
0.572
|
Medical history, n (%)
|
Hypertension
|
1511 (62.5)
|
1210 (61.6)
|
301 (66.3)
|
0.061
|
Prior MI
|
527 (21.8)
|
348 (17.7)
|
179 (39.4)
|
< 0.001
|
Prior PCI
|
414 (17.1)
|
280 (14.2)
|
134 (29.5)
|
< 0.001
|
Prior CABG
|
55 (2.3)
|
23 (1.2)
|
32 (7.0)
|
< 0.001
|
Prior stroke
|
281 (11.6)
|
204 (10.4)
|
77 (17.0)
|
< 0.001
|
Prior PAD
|
84 (3.5)
|
63 (3.2)
|
21 (4.6)
|
0.137
|
Glycometabolic status
|
Non-diabetes
|
926 (38.3)
|
829 (42.2)
|
97 (21.4)
|
< 0.001
|
Pre-diabetes
|
645 (26.7)
|
531 (27.0)
|
114 (25.1)
|
0.406
|
Diabetes
|
848 (35.1)
|
605 (30.8)
|
243 (53.5)
|
< 0.001
|
Laboratory results
|
TGs, mmol/L
|
1.84 ± 1.32
|
1.69 ± 1.05
|
2.47 ± 2.00
|
< 0.001
|
TC, mmol/L
|
4.17 ± 1.06
|
4.14 ± 1.05
|
4.33 ± 1.07
|
0.001
|
LDL-C, mmol/L
|
2.50 ± 0.88
|
2.50 ± 0.89
|
2.50 ± 0.85
|
0.962
|
HDL-C, mmol/L
|
0.98 ± 0.23
|
0.99 ± 0.24
|
0.92 ± 0.21
|
< 0.001
|
Estimated RLP-C, mmol/L
|
0.69 ± 0.42
|
0.65 ± 0.35
|
0.90 ± 0.61
|
< 0.001
|
hs-CRP, mg/L
|
1.29 (0.58, 3.31)
|
1.22 (0.53, 3.06)
|
1.87 (0.77, 4.29)
|
< 0.001
|
Creatinine, μmol/L
|
76.00 ± 16.95
|
75.68 ± 16.49
|
77.42 ± 18.76
|
0.048
|
eGFR, ml/(min*1.73m2)
|
93.49 ± 20.36
|
94.09 ± 20.11
|
90.91 ± 21.22
|
0.003
|
Uric acid, μmol/L
|
346.22 ± 82.64
|
346.45 ± 81.45
|
345.21 ± 87.69
|
0.774
|
FBG, mmol/L
|
6.20 ± 1.94
|
6.01 ± 1.71
|
7.03 ± 2.57
|
< 0.001
|
HbA1c, %
|
5.90 (5.50, 6.60)
|
5.80 (5.50, 6.40)
|
6.40 (5.80, 8.00)
|
< 0.001
|
LVEF, %
|
65.00 (60.00, 68.00)
|
65.00 (61.00, 69.00)
|
63.00 (57.00, 67.00)
|
< 0.001
|
Initial diagnosis, n (%)
| | | |
0.001
|
UA
|
2018 (83.4)
|
1662 (84.6)
|
356 (78.4)
| |
NSTEMI
|
401 (16.6)
|
303 (15.4)
|
98 (21.6)
| |
Medical treatment, n (%)
|
ACEI
|
734 (30.3)
|
577 (29.4)
|
157 (34.6)
|
0.029
|
ARB
|
948 (39.2)
|
753 (38.3)
|
195 (43.0)
|
0.068
|
Aspirin
|
2417 (99.9)
|
1963 (99.9)
|
454 (100.0)
|
0.496
|
Clopidogrel
|
2415 (99.8)
|
1963 (99.9)
|
452 (99.6)
|
0.109
|
β-Blocker
|
2199 (90.9)
|
1780 (90.6)
|
419 (92.3)
|
0.255
|
Statins
|
2366 (97.8)
|
1922 (97.8)
|
444 (97.8)
|
0.985
|
Oral hypoglycemic agents
|
437 (18.1)
|
314 (16.0)
|
123 (27.1)
|
< 0.001
|
Insulin
|
232 (9.6)
|
154 (7.8)
|
78 (17.2)
|
< 0.001
|
Angiographic data, n (%)
|
Left main disease
|
110 (4.5)
|
64 (3.3)
|
46 (10.1)
|
< 0.001
|
Multi-vessel disease
|
1631 (67.4)
|
1225 (62.3)
|
406 (89.4)
|
< 0.001
|
Chronic total occlusion
|
345 (14.3)
|
202 (10.3)
|
143 (31.5)
|
< 0.001
|
Diffuse lesion
|
605 (25.0)
|
431 (21.9)
|
174 (38.3)
|
< 0.001
|
Bifurcation lesion
|
492 (20.3)
|
368 (18.7)
|
124 (27.3)
|
< 0.001
|
Number of stents
|
1.96 ± 1.29
|
1.87 ± 1.14
|
2.33 ± 1.76
|
< 0.001
|
- Bold values indicate statistically significant associations
- BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, CAD Coronary artery disease, MI Myocardial infarction, PCI Percutaneous coronary intervention, CABG Coronary artery bypass grafting, PAD Peripheral arterial disease, TGs Triglycerides, TC Total cholesterol, LDL-C Low-density lipoprotein cholesterol, HDL-C High-density lipoprotein cholesterol, RLP-C Remnant-like particle cholesterol, hs-CRP High-sensitivity C-reactive protein, eGFR Estimated glomerular filtration rate, FBG Fasting blood glucose, HbA1c Glycosylated hemoglobin A1c, LVEF Left ventricular ejection fraction, UA Unstable angina, NSTEMI Non-ST-segment elevation myocardial infarction, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker